Fate Therapeutics GAAP EPS of -$0.26 beats by $0.02, revenue of $1.3M misses by $0.25M
Source: SeekingAlpha
2026-05-13 08:34:42 ET
More on Fate Therapeutics
- Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026
- Seeking Alpha’s Quant Rating on Fate Therapeutics
- Historical earnings data for Fate Therapeutics
- Financial information for Fate Therapeutics
Read the full article on Seeking Alpha
For further details see:
Fate Therapeutics GAAP EPS of -$0.26 beats by $0.02, revenue of $1.3M misses by $0.25M
Fate Therapeutics Inc.
NASDAQ: FATE
FATE Trading
7.56% G/L:
$1.98 Last:
2,318,446 Volume:
$2.02 Open:
FATE Latest News
May 13, 2026 08:30:00 am
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 11, 2026 08:30:00 am
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
FATE Stock Data
$128,041,041
108,996,378
1.54%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
